AVROBIO, Inc. IPO Research Information

AVROBIO, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on AVROBIO, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
AVROBIO, Inc.	AVRO - NASDAQ	$16.00-$18.00	$19.00	$29.25	5.2 million	6/21/2018
Underwriter(s): Morgan Stanley, Cowen, Wells Fargo Securities
Co-Manager(s): Wedbush Pacgrow
Industry: Health Care
Filing(s): Filed 2018-05-25 Terms Added 2018-06-11 Final Prospectus 2018-06-21

AVROBIO, Inc. Quote & Chart - Click for current quote - AVRO

About AVROBIO, Inc. (adapted from AVROBIO, Inc. prospectus):
They are a clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "AVRO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.